Zepbound vs Wegovy: Which GLP-1 Is Right for You?

Zepbound vs Wegovy: Which GLP-1 Is Right for You?

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026. We have no commercial relationship with Eli Lilly or Novo Nordisk.

Zepbound (tirzepatide) and Wegovy (semaglutide 2.4mg) are the two FDA-approved GLP-1 medications specifically approved for chronic weight management. In the only randomized head-to-head trial, Zepbound produced 20.2% body weight loss versus 13.7% for Wegovy — a 47% relative advantage. But Wegovy has a proven cardiovascular outcomes benefit, an oral pill option, adolescent approval, and lower self-pay cost for patients not using insurance.

The short version: Zepbound produces more weight loss and has lower GI side effect rates. Wegovy is the only option with a cardiovascular risk-reduction approval, an oral formulation, and proven data in adolescents. Cost with insurance is comparable; Wegovy wins on self-pay if you use the oral formulation.

Zepbound produced 47% greater relative weight loss than Wegovy in the only head-to-head clinical trial — 20.2% vs 13.7% at maximum FDA-approved doses (SURMOUNT-5, 72 weeks). Neither drug has been compared in a direct head-to-head trial of primary cardiovascular outcomes.

---

What Is the Quick Summary of Zepbound vs Wegovy?

	Zepbound	Wegovy
Active ingredient	Tirzepatide	Semaglutide 2.4mg
Mechanism	Dual GIP/GLP-1 agonist	GLP-1 agonist
Manufacturer	Eli Lilly	Novo Nordisk
Mean weight loss (head-to-head)	20.2%	13.7%
Administration	Weekly injection	Weekly injection or daily pill
Self-pay — injection	$299–$449/mo (LillyDirect)	~$1,349/mo list; $499/mo via NovoCare Direct
Self-pay — oral option	None	$149–$299/mo (oral Wegovy)
Cardiovascular risk-reduction approval	No	Yes (SELECT trial)
Adolescent approval (12+)	No	Yes
Obstructive sleep apnea approval	Yes	No

---

How Do Zepbound and Wegovy Work Differently?

Both drugs mimic the gut hormone GLP-1, which reduces appetite by acting on brain hunger centers, slows gastric emptying so you feel full longer, and improves insulin sensitivity. The mechanism diverges there.

Wegovy (semaglutide) is a GLP-1 receptor agonist — single target, single mechanism. It is the same active ingredient as Ozempic, dosed differently (2.4mg weekly for obesity vs up to 2mg for type 2 diabetes). Wegovy and Ozempic are not the same drug and should not be treated interchangeably; the obesity indication, dose, and prescribing context differ.

Zepbound (tirzepatide) activates both the GLP-1 receptor and the GIP receptor — a dual-agonist mechanism. GIP activation may enhance fat metabolism and provide additional metabolic benefit beyond GLP-1 alone. Whether that explains Zepbound's greater weight loss is still being studied, but the dual-agonist mechanism is consistently cited as the leading hypothesis.

---

What Does the Clinical Evidence Show for Weight Loss?

SURMOUNT-5 Trial — Direct Head-to-Head (2024)

The only randomized trial that compared both drugs directly at maximum FDA-approved doses:

Metric	Zepbound 15mg	Wegovy 2.4mg
Mean weight loss	20.2%	13.7%
Achieved ≥5% loss	93%	84%
Achieved ≥10% loss	82%	66%
Achieved ≥15% loss	70%	45%
Achieved ≥20% loss	54%	30%
Trial duration	72 weeks	72 weeks

At every threshold, a higher percentage of Zepbound patients reached the target.

Individual Trial Data

Trial	Drug	Duration	Mean Weight Loss
SURMOUNT-1	Tirzepatide 15mg	72 weeks	22.5%
SURMOUNT-1	Tirzepatide 10mg	72 weeks	21.4%
STEP 1	Semaglutide 2.4mg	68 weeks	14.9%
OASIS 4	Oral semaglutide 25mg	64 weeks	16.6% (adherent)

Real-World Data

A 2026 retrospective study of U.S. patients found tirzepatide produced 11.2% weight loss at 6 months versus 8.8% for semaglutide. Real-world results run lower than trials due to variable adherence, but the relative tirzepatide advantage persisted. These are observational findings, not randomized data.

---

How Do Zepbound and Wegovy Compare on Side Effects?

Both drugs share the same GI-dominant side effect profile. Zepbound's rates are lower in trial populations:

Side Effect	Zepbound (SURMOUNT-1)	Wegovy (STEP 1)
Nausea	24–33%	44%
Diarrhea	18–23%	30%
Vomiting	9–13%	24%
Constipation	17–21%	24%
Headache	8–12%	14%
Discontinued due to side effects	4.3–7.1%	7.0%

The lower nausea and vomiting rates for Zepbound are counterintuitive given the dual mechanism, but they are consistent across trials.

Shared black box warning: Both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Thyroid C-cell tumors were observed in rodent studies; the clinical relevance to humans has not been established, but the warning applies to both drugs.

Other serious but rare risks (both drugs): pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia (in patients taking insulin or insulin secretagogues). These are monitored by prescribing physicians.

For a detailed breakdown, see our tirzepatide side effects guide and Wegovy side effects guide.

---

How Do Zepbound and Wegovy Compare on Price?

Pricing last verified April 2026. We update pricing data monthly.

Self-Pay Pricing — Zepbound

Eli Lilly lowered self-pay prices in February 2026 via single-dose vials through LillyDirect. The $449 pricing for all doses at or above 7.5mg is applied automatically — no coupon required.

Dose	Monthly Cost
2.5 mg (starting)	$299
5 mg	$399
7.5 mg	$449
10 mg	$449
12.5 mg	$449
15 mg (maintenance)	$449

Self-Pay Pricing — Wegovy

The introduction of oral Wegovy in late 2025 created a significantly cheaper self-pay pathway for semaglutide.

Option	Monthly Cost
Injectable Wegovy (list price)	~$1,349
Injectable via NovoCare Direct (cash-pay)	$499
Oral Wegovy — 1.5mg or 4mg (starter)	$149
Oral Wegovy — 9mg	$299
Oral Wegovy — 25mg (maintenance)	$299

For patients paying cash, oral Wegovy at $299/month maintenance is substantially cheaper than Zepbound at $449/month. The trade-off is less weight loss on average.

With Commercial Insurance

Both drugs can reach low copay levels with commercial insurance plus a manufacturer savings card:

	Zepbound	Wegovy
With insurance + copay card	~$25/mo	$0–$25/mo
Self-pay (no insurance)	$449/mo (injection)	$299/mo (oral)

Coverage requires a qualifying obesity diagnosis (BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity). Prior authorization is standard. As of April 2026, Medicare does not cover either drug for weight loss; broader Medicare coverage through the Bridge program is projected for a July 2026 start, with implementation details still being finalized.

For a full cost breakdown by dose and provider, see our tirzepatide cost guide and semaglutide cost guide.

---

What Are the Dosing Schedules for Each Drug?

Zepbound (Weekly Injection)

Weeks	Dose
1–4	2.5 mg
5–8	5.0 mg
9–12	7.5 mg
13–16	10 mg
17–20	12.5 mg
21+	15 mg (or lowest effective dose)

Wegovy — Injectable (Weekly)

Weeks	Dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg

Wegovy — Oral (Daily)

Days	Dose
1–30	1.5 mg
31–60	4 mg
61–90	9 mg
91+	25 mg

Zepbound's titration schedule is longer (20 weeks to maximum dose vs 16 weeks for injectable Wegovy). Both injectable forms use an auto-injector pen. Oral Wegovy requires a 30-minute fasting window before taking; a meal or drink cannot follow for 30 minutes.

---

What Additional FDA Approvals Does Each Drug Have?

Wegovy has a more expansive approval profile beyond weight loss:

Approval	Zepbound	Wegovy
Weight management (adults)	Yes	Yes
Weight management (adolescents 12+)	No	Yes
Cardiovascular risk reduction	No	Yes (SELECT trial, 20% reduction in MACE)
MASH / metabolic-associated steatohepatitis	No	Yes
Obstructive sleep apnea	Yes (SURMOUNT-OSA)	No

Wegovy's cardiovascular risk-reduction approval is based on the SELECT trial (20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease). This is a meaningful differentiator for patients with heart disease or significant cardiovascular risk factors. Zepbound has cardiovascular outcomes trials ongoing but no approval as of April 2026.

---

Which Should You Choose — Zepbound or Wegovy?

Zepbound may be the better fit if:

• Maximizing weight loss is the primary goal — 20.2% vs 13.7% in head-to-head data
• GI side effects are a concern — lower nausea and vomiting rates in trials
• You have obstructive sleep apnea — FDA-approved indication
• Your insurance covers Zepbound and the copay is comparable to Wegovy

Wegovy may be the better fit if:

• You want an oral medication and cannot or will not self-inject
• You have cardiovascular disease or significant cardiovascular risk — proven CV risk-reduction approval
• Self-pay cost is the primary constraint — oral Wegovy at $299/month vs Zepbound at $449/month
• You are under 18 — Wegovy is approved for adolescents age 12 and older
• You have MASH/fatty liver disease — FDA-approved indication

For most patients

If insurance covers both and cardiovascular history is not a factor, Zepbound's superior efficacy and lower GI side effect profile give it an edge. Wegovy is highly effective — 14.9% average weight loss in STEP 1 is clinically meaningful, and the oral option eliminates the injection barrier. The best medication is the one your prescriber recommends based on your specific history, that you can access and afford long-term, and that you'll take consistently.

---

How We Evaluated Zepbound vs Wegovy

This comparison is based on: published trial data (SURMOUNT-5, SURMOUNT-1, STEP 1, OASIS 4, SELECT), FDA prescribing information for both drugs, current self-pay pricing verified from LillyDirect and NovoCare Pharmacy Direct, and manufacturer savings program terms. We do not accept payment from Eli Lilly, Novo Nordisk, or any GLP-1 manufacturer for placement or coverage. Revenue from this site never influences drug comparisons. See our methodology for the full editorial policy.

---

Frequently Asked Questions

Is Zepbound better than Wegovy for weight loss?

In the only randomized head-to-head trial (SURMOUNT-5), Zepbound produced 20.2% mean body weight loss compared to 13.7% for Wegovy at maximum FDA-approved doses over 72 weeks — a 47% relative advantage. These are trial populations; real-world results are lower. The relative advantage of tirzepatide has held in retrospective real-world data (11.2% vs 8.8% at 6 months in a 2026 study). Trial comparisons to SURMOUNT-1 and STEP 1 (which were not head-to-head) also favor tirzepatide, but cross-trial comparisons carry more uncertainty.

Which has fewer side effects — Zepbound or Wegovy?

Zepbound has lower nausea (24–33% vs 44%) and vomiting (9–13% vs 24%) rates in clinical trial data. Both drugs share similar serious risk profiles — thyroid C-cell tumor warning (black box), pancreatitis, gallbladder disease, and kidney risk. Neither drug is clearly "safer" overall. Wegovy has more long-term safety follow-up data given its earlier approval.

Can you switch from Wegovy to Zepbound?

Yes, under medical supervision. When switching from semaglutide to tirzepatide, you start tirzepatide at the 2.5mg starting dose regardless of your previous semaglutide dose — there is no validated dose conversion. Your prescriber should guide the transition timing and monitor for side effects.

Does insurance cover both Zepbound and Wegovy?

Both require a qualifying obesity diagnosis and prior authorization. Commercial insurance with manufacturer savings cards can reduce out-of-pocket costs to $0–$25/month for Wegovy and ~$25/month for Zepbound. As of April 2026, Medicare does not cover either drug for weight loss. Expanded Medicare coverage through the Bridge program is projected for July 2026 with a target ~$50/month copay — implementation details are still being finalized.

Can you take Zepbound and Wegovy at the same time?

No. The drugs work through overlapping mechanisms and should not be combined. Combining them would increase side effect risk without established benefit. If switching between them, do so under physician guidance.

---

For current pricing by dose, see our tirzepatide cost guide and semaglutide cost guide. For the full GLP-1 provider landscape, see our best GLP-1 telehealth providers comparison.

This comparison is for informational purposes only and does not constitute medical advice. Consult your healthcare provider to determine which medication is appropriate for your individual situation. Pricing reflects publicly available rates as of April 2026.